NCT02018536 - A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2336805 Alone and With the Co-administration of TMC435 in Healthy Japanese Participants. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions

Healthy

Interventions

DRUG

GSK2336805 30 mg

A single dose of 1 tablet of 30 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.

DRUG

GSK2336805 60 mg

A single dose of 2 tablets of 30 mg ie, 60 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.

DRUG

GSK2336805 120 mg

A single dose of 4 tablets of 30 mg ie, 120 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.

DRUG

TMC435 150 mg (Treatment A)

1 capsule of TMC435 150 mg taken once daily orally (by mouth) on Days 1 to 7 under fed conditions.

DRUG

GSK2336805 60 mg (Treatment B and part of Treatment C and D)

2 tablets of 30 mg GSK2336805 ie, 60 mg of GSK2336805 taken once daily orally (by mouth) on Days 1 to 7 under fed conditions.

DRUG

TMC435 100 mg (part of Treatment C)

1 capsule of TMC435 100 mg taken orally (by mouth) on Days 1 to 7 under fed conditions.

DRUG

TMC435 150 mg (part of treatment D)

1 capsule of TMC435 150 mg taken orally (by mouth) on Days 1 to 7 under fed conditions.

Trial Locations (1)

Cypress

All Listed Sponsors

lead

Janssen R&D Ireland

INDUSTRY